ABSTRACT -The effects of hyaluronan (HA) on the release of arachidonic acid (AA) from phospho lipids induced by bradykinin in synovial fibroblasts of osteoarthritic patients were examined. HA inhib ited [14C]AA release from prelabeled synovial cells stimulated with and without bradykinin 1 hr after incubation with HA and thereafter. Pain is a cardinal symptom of osteoarthritis. Current treatments for osteoarthritis using steroidal and non steroidal anti-inflammatory agents focus on relieving pain arising from secondarily induced synovitis. Brady kinin is a potent pain-producing nonapeptide which is formed in damaged tissues (1). This peptide binds to receptors on the cell surface and triggers activations of both phospholipase-A2 and -C simultaneously (2, 3). These phospholipases directly or indirectly generate free arachidonic acid (AA) by hydrolysis of phospho lipids (4). Calcium-ionophore A23187 has also been known to activate phospholipase A2 by directly increas ing the intracellular calcium level (5). Bradykinin-in duced pain is amplified by prostaglandin E2, which sensitizes nociceptors in peripheral tissues (6). Since the formation of cyclooxygenase-derived products is de pendent on prior release of AA (7, 8), inhibition of the AA release from phospholipids may result in the relief of pain.
Pain is a cardinal symptom of osteoarthritis. Current treatments for osteoarthritis using steroidal and non steroidal anti-inflammatory agents focus on relieving pain arising from secondarily induced synovitis. Brady kinin is a potent pain-producing nonapeptide which is formed in damaged tissues (1) . This peptide binds to receptors on the cell surface and triggers activations of both phospholipase-A2 and -C simultaneously (2, 3) . These phospholipases directly or indirectly generate free arachidonic acid (AA) by hydrolysis of phospho lipids (4) . Calcium-ionophore A23187 has also been known to activate phospholipase A2 by directly increas ing the intracellular calcium level (5) . Bradykinin-in duced pain is amplified by prostaglandin E2, which sensitizes nociceptors in peripheral tissues (6) . Since the formation of cyclooxygenase-derived products is de pendent on prior release of AA (7, 8) , inhibition of the AA release from phospholipids may result in the relief of pain.
Hyaluronan (HA), a major component of the joint synovial fluid, is a linear polysaccharide composed of alternating units of N-acetyl-D-glucosamine and D-glu curonic acid (9) . In inflammatory arthritis, synovial HA is reduced in concentration, fragmented and depoly merized with a concomitant reduction in synovial fluid viscosity (10) . In recent years, clinical trials of intra articular administration of HA to patients with osteo arthritis have indicated its analgesic effects (11, 12) . Thus, effects of HA with various molecular weights on the AA release from synovial fibroblasts of osteo arthritic patients were examined in this study to deter mine if this polymer actually inhibits the AA release.
MATERIALS AND METHODS

Hyaluronan
Four endotoxin-free HA preparations of different molecular weights (viscosity-average Mr: 2.0 X 106, 1.4 X 106, 9.8 X 105, and 2.8 X 105) were products pre viously purified (protein content less than 0.1%) from culture broths of Streptococcus zooepidemicus (13) (gifts from Shiseido Pharmaceutical Research Labora tories, Japan). HA preparations derived from pig skin (Mr 4.0 6.0 X 104, more than 95% pure) and human umbilical cord (Mr 0.8 1.2 X 106, protein content less than 0.1%) were products of Seikagaku Kogyo, Japan.
Synovial cells
Synovium from the knee of osteoarthritic patients was isolated from surrounding tissues at the time of surgery for treating arthropathy and minced into 1 2 min 2 fragments. Synovial fragments were explanted onto 60-mm diameter culture dishes containing Dulbec co's modified Eagle's medium (DMEM; Flow Labora tories, USA) supplemented with 20% heat-inactivated fetal bovine serum (FBS; Flow Laboratories, USA), 100 U/ml of penicillin (Meiji Seika, Japan) and 100 ,ug/ml of streptomycin (Meiji Seika, Japan). They were cultured at 37°C in a humidified 5% CO2 atmosphere. Morphologically fibroblast-like cell out-growths from synovial fragments were trypsinized, seeded at a density of 4 X 104 cells/well in 24-well cell culture plates and allowed to grow to confluence.
Release of AA from synovial cells Confluent synovial cells were prelabeled with [1 14C]AA (1 .4 kBq/0.5 ml/well, 1.9 GBq/mmole, New England Nuclear, USA) in DMEM containing 10% FBS for 24 hr at 37°C. After washing 3 times with serum-free DMEM, the labeled cells were exposed for 3 hr to 0.5 ml/well of DMEM containing 10% FBS with bradykinin (10,uM, Bachem, USA), calcium-ionophore A23187 (1 pM, Sigma, USA), or vehicle in the pres ence or absence of HA with different molecular weights at 0.5, 1.0 and 1.5 mg/ml. In place of HA treatment, 0.4, 1.5 or 4.0 mg/ml of methyl cellulose (MC; Tokyo Kasei, Japan) was added to other cultures to evaluate the effect of viscosity. At the end of the treatment period, the culture medium was collected and centri fuged at 2000 X g for 15 min at room temperature to avoid any contamination of free cells or cell debris. The supernatant was isolated and its radioactivity was meas ured by a liquid scintillation counter.
Incorporation of AA in synovial cells
Confluent synovial cells were incubated with [14C]AA (1.2 kBq/0.5 ml/well) in DMEM containing 10% FBS with or without HA (1.5 mg/ml, Mr 2.0 X 106) at 37°C for various intervals. At the end of incubation, the re sidual radioactivity in the medium was measured.
Analyses of lipids in cells and medium Total lipid contents were extracted under HCl-acidi fied conditions by the method of Folch et al. (14) . The resulting organic phase was analyzed by thinlayer chro matography with a silica gel 60-precoated plate (Merck, Germany). The solvent system used to separate phos pholipids, AA, diacylglycerol and triacylglycerol in the cell extracts was petroleum ether / diethylether / acetic acid (50/50/1, v/v). Chloroform / methanol (93/7, v/v) was employed to analyze AA in the medium extract. Lipid standards were run as carriers with each sample. Lipid spots visualized with iodine vapor were removed, and the radioactivity was then determined.
Viscosity determinations
HA (1.5 mg/ml) and MC (0.4, 1.5 and 4.0 mg/ml) were prepared in DMEM containing 10% FBS. The viscosity (expressed in centipoise, cP) of the polysac charide solution was measured by a calibrated rota tional type viscometer (Tokyo Keiki, Japan) at 37°C. Bacterial HA preparations (1.5 mg/ml) of Mr 2.0 X 106, 1.4 X 106, 9.8 X 105 and 2.8 X 105 registered 14.5, 8.1, 3.8 and 1.8 cP, respectively. HA preparations de rived from pig skin and human umbilical cord (1.5 mg/ml) had viscosities of 1.1 and 5.1 cP, respectively. The viscosity values of MC samples of 0.4, 1.5 and 4.0 mg/ml were 3.1, 7.6 and 12.9 cP, respectively. The vis cosity of the medium was 0.6 cP.
Statistical analyses
Results were expressed as means ± S.D. The statis tical significance of data was evaluated by the unpaired Student's t-test.
RESULTS [14CJAA metabolites in cells and medium
On labeling synovial cells with [14C]AA (6.3 X 104 dpm) for 24 hr, 4.7 X 104 dpm of the radiolabeled com pound were incorporated within the cells. Of the [14C]AA incorporated in cells, 87% of the counts were found in [14C]phospholipids (4.1 X 104 dpm) and 7.9%, in [14C]triacylglycerol (3.7 X 103 dpm), whereas the amounts of [14C]diacylglycerol and [14C]AA were neg ligible (less than 1000 dpm in both). In labeled cells in cubated for 3 hr in the absence (control) or presence of bradykinin (10,uM) or A23187 (1 pM), the highest re lease (11.3%) of incorporated radiolabeled ligand was induced by bradykinin, as compared to those of the control (5.5%) and A23187 (9.7%). When free
[14C]AA contents against the total releases in media in cubated with bradykinin, A23187 or neither were ex pressed as a percentage, the values were 82.2%, 77.2% or 64.1%, respectively. Therefore, the release of (Fig. 2) . HA with a higher molecular weight manifested more potent inhibitory effects on [14C]AA release than the same polymer with a lower molecular weight. Especially at a concentration of 1.5 mg/ml, HA had an inhibitory tendency consistent with the statistical significances achieved with different molecular weights (Fig. 2) . When prelabeled synovial cells were stimu lated for 3 hr with A23187 (1,uM), HA (Mr 2.0 X 106) also inhibited [14C]AA release in a dose-dependent manner (Fig. 3) . (Table 1) . ). Significant differences of P < 0.05 (* ), P < 0.01 (* * ), and P < 0.001 (* * *) were values compared to each con trol. The inhibitory effects of HA were dependent on both the concentration and molecular weight of the polymer. Because MC at a high concentration (4.0 mg/ml) also suppressed the bradykinin-induced [14C]AA release from synovial cells, the inhibitory effects of HA with a high molecular weight are probably, at least in part, due to its viscosity, which may affect the mobility of AA molecules from the cell surface. However, unlike MC, HA manifested significant inhibitory effects on
[14C]AA release at lower viscosities. This result sug gests that the inhibitory effects of HA on [14C]AA re lease from cells are not merely a consequence of the in creased viscosity of the medium, but also factors other than viscosity may be involved in the inhibitory effects of HA. HA had no significant effect on the quantitative
[14C]AA release stimulated in the presence or absence of bradykinin for an incubation period of up to 45 min. Because of its viscosity, HA may require the initial 1 hr or more to infiltrate the cell surface so as to elicit sig nificant inhibitory effects. However, it remains unclear whether or not the time-lag in the inhibition of [14C]AA release can be accounted for merely by the viscosity of HA.
While a plausible mechanism for the inhibition of
[14C]AA release by HA is not known at present, de creased AA levels by HA in the extracellular space may result in the diminished production of eicosanoids in joint synovial fluid, since AA is taken up by other cells such as activated leukocytes infiltrated in the joint space and is then metabolized to eicosanoids (15) . We used cultured human synovial cells as a model to evalu ate the in vitro effects of HA on articular tissues. Our results obtained from this model coincide well with a recent observation on the in vivo inhibitory action of HA on prostaglandin E2 production in the synovial fluid of arthritic patients (16) . As such, intra-articular administration of HA with a high molecular weight may be effective for treating inflammatory arthritis.
